Evolus (EOLS) Change in Account Payables (2017 - 2026)
Evolus' (EOLS) quarterly Change in Account Payables came in at -$7.6 million in Q1 2026, down 261.14% YoY from $4.7 million in Q1 2025, and down 471.9% on a QoQ basis from $2.0 million in Q4 2025.
Evolus (EOLS) Change in Account Payables (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Change in Account Payables data on file, last reported at -$7.6 million in Q1 2026.
- Quarterly Change in Account Payables fell 261.14% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 153.0% YoY) and the FY2025 annual result came in at $10.1 million, up 2483.89% from the prior year.
- Change in Account Payables slipped to -$7.6 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $4.7 million in Q1 2025 to a low of -$7.6 million in Q1 2026.
- A 5-year average of $166823.5 and a median of $909000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 1028.57% — and 2024, when it plunged 508.13%.
- Tracing EOLS's Change in Account Payables over 5 years: stood at -$1.4 million in 2022, then sank by 323.8% to -$5.8 million in 2023, then jumped by 50.24% to -$2.9 million in 2024, then jumped by 170.82% to $2.0 million in 2025, then slumped by 471.9% to -$7.6 million in 2026.
- The last three Change in Account Payables figures came in at -$7.6 million (Q1 2026), $2.0 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.63 Mn |
| Jun 30, 2026 | 2.63 Mn |
| Mar 31, 2026 | -7.61 Mn |
| Mar 31, 2026 | -7.61 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Dec 31, 2025 | 2.05 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Sep 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | -777,000.00 |
| Jun 30, 2025 | -777,000.00 |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | 909,000.00 |
| Mar 31, 2024 | 909,000.00 |